Drug

Methscopolamine

As of the edition of 20 October 2026, Methscopolamine is a small molecule: marketed, first approved in 1982 (US); acts on CHRM1 and CHRM3; no US protection is listed.

Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.

The drug

Status
Marketed; latest approval 1982
Kind
Small molecule
Brand name
Pamine
First approved
1 January 1982 (US)
Approvals on record
2 in 1 region
Holder of the most recent approval
Fougera Pharmaceuticals

US protection

No US protection is listed.

The FDA registers list no drug-substance patent or exclusivity that counts for this drug.

This is the US only.

Targets

GeneProteinUniProt
CHRM1Muscarinic acetylcholine receptor M1P11229
CHRM3Muscarinic acetylcholine receptor M3P20309

Who has held its approvals

CompanyRoleYears
Fougera PharmaceuticalsAcquired holder2026 to now
PfizerEarlier holder